6.
Machelska H
. Dual peripheral actions of immune cells in neuropathic pain. Arch Immunol Ther Exp (Warsz). 2011; 59(1):11-24.
DOI: 10.1007/s00005-010-0106-x.
View
7.
Vadivelu N, Mitra S, Hines R
. Peripheral opioid receptor agonists for analgesia: a comprehensive review. J Opioid Manag. 2011; 7(1):55-68.
DOI: 10.5055/jom.2011.0049.
View
8.
Law P, Reggio P, Loh H
. Opioid receptors: toward separation of analgesic from undesirable effects. Trends Biochem Sci. 2013; 38(6):275-82.
PMC: 3665630.
DOI: 10.1016/j.tibs.2013.03.003.
View
9.
Vowles K, McEntee M, Julnes P, Frohe T, Ney J, van der Goes D
. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015; 156(4):569-576.
DOI: 10.1097/01.j.pain.0000460357.01998.f1.
View
10.
Quallo T, Alkhatib O, Gentry C, Andersson D, Bevan S
. G protein βγ subunits inhibit TRPM3 ion channels in sensory neurons. Elife. 2017; 6.
PMC: 5593501.
DOI: 10.7554/eLife.26138.
View
11.
Schmid C, Kennedy N, Ross N, Lovell K, Yue Z, Morgenweck J
. Bias Factor and Therapeutic Window Correlate to Predict Safer Opioid Analgesics. Cell. 2017; 171(5):1165-1175.e13.
PMC: 5731250.
DOI: 10.1016/j.cell.2017.10.035.
View
12.
Dowell D, Haegerich T, Chou R
. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016; 315(15):1624-45.
PMC: 6390846.
DOI: 10.1001/jama.2016.1464.
View
13.
Wieschowski S, Chin W, Federico C, Sievers S, Kimmelman J, Strech D
. Preclinical efficacy studies in investigator brochures: Do they enable risk-benefit assessment?. PLoS Biol. 2018; 16(4):e2004879.
PMC: 5886385.
DOI: 10.1371/journal.pbio.2004879.
View
14.
Williams J, Ingram S, Henderson G, Chavkin C, Von Zastrow M, Schulz S
. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013; 65(1):223-54.
PMC: 3565916.
DOI: 10.1124/pr.112.005942.
View
15.
Viscusi E, Webster L, Kuss M, Daniels S, Bolognese J, Zuckerman S
. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain. 2015; 157(1):264-272.
DOI: 10.1097/j.pain.0000000000000363.
View
16.
Spahn V, Stein C
. Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development. Expert Opin Investig Drugs. 2016; 26(2):155-160.
DOI: 10.1080/13543784.2017.1275562.
View
17.
Montandon G, Ren J, Victoria N, Liu H, Wickman K, Greer J
. G-protein-gated Inwardly Rectifying Potassium Channels Modulate Respiratory Depression by Opioids. Anesthesiology. 2015; 124(3):641-50.
PMC: 4755838.
DOI: 10.1097/ALN.0000000000000984.
View
18.
Yekkirala A, Roberson D, Bean B, Woolf C
. Breaking barriers to novel analgesic drug development. Nat Rev Drug Discov. 2017; 16(8):545-564.
PMC: 5675565.
DOI: 10.1038/nrd.2017.87.
View
19.
Reinecke H, Weber C, Lange K, Simon M, Stein C, Sorgatz H
. Analgesic efficacy of opioids in chronic pain: recent meta-analyses. Br J Pharmacol. 2014; 172(2):324-33.
PMC: 4292950.
DOI: 10.1111/bph.12634.
View
20.
Li Y, van den Pol A
. Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system. J Neurosci. 2008; 28(11):2814-9.
PMC: 6670680.
DOI: 10.1523/JNEUROSCI.5447-07.2008.
View